Recombinant Human BMPR-IA

Using Recombinant Human BMPR-IA (Bone Morphogenetic Protein Receptor Type IA, also known as ALK-3) in research applications is valuable for studying cellular signaling, tissue development, regenerative medicine, and bone biology. This recombinant protein enables precise, reproducible investigation of BMPR-IA-mediated pathways and functions in vitro and in vivo.

Key reasons to use Recombinant Human BMPR-IA in research:

• Elucidation of Signaling Pathways: BMPR-IA is a critical receptor in the BMP (Bone Morphogenetic Protein) signaling pathway, which regulates cell differentiation, proliferation, and apoptosis in various tissues. Recombinant BMPR-IA allows controlled studies of ligand-receptor interactions, downstream signaling, and pathway modulation.
• Developmental Biology: BMPR-IA is essential for embryonic development, including anterior-posterior axis formation, heart, lung, and palate morphogenesis. Recombinant protein enables mechanistic studies of these developmental processes.
• Regenerative Medicine and Bone Research: BMPR-IA plays a pivotal role in bone formation and repair. Recombinant BMPR-IA can be used to investigate osteogenic differentiation, bone regeneration, and the effects of BMP ligands or inhibitors in tissue engineering models.
• Drug Discovery and Screening: Recombinant BMPR-IA is used in high-throughput screening assays to identify small molecules or biologics that modulate BMP signaling, supporting drug development for skeletal disorders, fibrosis, and cancer.
• Functional and Structural Studies: Recombinant proteins are indispensable for biochemical assays, structural biology (e.g., crystallography, NMR), and binding studies, providing insights into receptor structure, ligand specificity, and mechanism of action.
• Diagnostic and Therapeutic Development: Recombinant BMPR-IA can serve as a tool for developing diagnostic assays or as a target for therapeutic intervention in diseases involving aberrant BMP signaling.

Advantages of using recombinant proteins include high purity, batch-to-batch consistency, and the ability to engineer specific tags or mutations for mechanistic studies.

In summary, Recombinant Human BMPR-IA is a versatile tool for dissecting BMP signaling, modeling developmental and regenerative processes, and advancing therapeutic discovery in bone and tissue biology.

Yes, you can use recombinant human BMPR-IA as a standard for quantification or calibration in ELISA assays, provided it is sufficiently pure and its concentration is accurately determined. This approach is widely accepted for quantitative ELISA, where a standard curve is generated using known concentrations of the target protein.

Essential context and best practices:

• Purity and Quantification: The recombinant BMPR-IA should be highly purified, as impurities can affect the accuracy of your standard curve. The concentration of the recombinant protein must be precisely measured, typically by absorbance at 280 nm, BCA assay, or HPLC.
• Standard Curve Preparation: Prepare a dilution series covering the expected range of your assay (e.g., 0.31–20 ng/mL or up to 200 ng/mL, depending on assay sensitivity). Use the same buffer as your samples to minimize matrix effects.
• Formulation: Recombinant BMPR-IA is often supplied lyophilized and may include carrier proteins such as BSA to enhance stability. Follow reconstitution instructions carefully and store aliquots at recommended temperatures to maintain activity.
• Validation: Confirm that your ELISA antibodies recognize the recombinant BMPR-IA in the same way as the native protein. Cross-reactivity or interference should be assessed, especially if other BMP family proteins or receptors are present in your samples.
• Data Analysis: Use appropriate curve-fitting methods (e.g., 4-PL or 5-PL) for standard curve generation and sample quantification.

Additional considerations:

• Interference: High concentrations of recombinant BMPR-IA (>10 ng/mL) may interfere with some BMP-2 ELISAs, so ensure your assay is specific for BMPR-IA and not BMP-2 or other related proteins.
• Lot-to-lot consistency: If using commercial recombinant BMPR-IA, check for lot-specific information such as endotoxin levels and bioactivity (ED50), as these can affect assay performance.
• Storage: Store reconstituted standards at -20°C or -80°C as recommended to preserve protein integrity.

In summary, recombinant human BMPR-IA is suitable as an ELISA standard if it is pure, accurately quantified, and validated for your specific assay system. This enables reliable calibration and quantification of BMPR-IA in biological samples.

Recombinant Human BMPR-IA (Bone Morphogenetic Protein Receptor Type IA) has been validated for several key applications in published research, primarily in studies of BMP signaling, osteogenesis, and reproductive biology.

Validated Applications in Published Research:

• Cell Signaling Studies: Recombinant BMPR-IA is widely used to investigate BMP signaling pathways, particularly its role as a type I receptor that complexes with BMP type II receptors to activate SMAD-dependent transcriptional responses. This is fundamental for understanding cellular differentiation and development.

• Functional Assays: It has been validated for use in in vitro assays measuring its ability to inhibit BMP-2-induced alkaline phosphatase production in C2C12 myogenic cells, which is a standard readout for BMP receptor activity and osteogenic differentiation.

• Protein-Protein Interaction Studies: Recombinant BMPR-IA is used to study binding interactions with BMP ligands and synthetic peptides, such as BMP-2-derived osteogenic peptides, to assess receptor activation and downstream signaling. For example, OP5, a synthetic peptide, was shown to bind BMPR-IA/II and activate the PKA/CREB pathway, demonstrating the receptor’s utility in ligand-binding and signaling assays.

• ELISA and Western Blot: Recombinant BMPR-IA is validated as a standard or control in ELISA and Western blot assays for the detection and quantification of BMPR-IA protein levels. These applications are essential for protein expression analysis in various cell and tissue samples.

• Reproductive Biology: BMPR-IA has been used to dissect the signaling mechanisms of anti-Müllerian hormone (AMH) in granulosa cells, demonstrating its necessity for AMH-induced gene expression and SMAD phosphorylation. siRNA knockdown experiments targeting BMPR-IA confirmed its critical role in AMH signaling pathways in ovarian cells.

Additional Context:

• Recombinant BMPR-IA is typically produced in mammalian expression systems to ensure proper folding and post-translational modifications, which are crucial for receptor functionality in signaling assays.
• It is not approved for clinical or diagnostic use; all applications are restricted to basic and preclinical research.

Summary Table:

These applications demonstrate the versatility of recombinant human BMPR-IA in elucidating BMP-related signaling mechanisms, osteogenic differentiation, and reproductive hormone pathways in published research.

To reconstitute and prepare Recombinant Human BMPR-IA (ALK-3) protein for cell culture experiments, first centrifuge the lyophilized vial to collect all powder at the bottom, then dissolve in sterile water or PBS to a final concentration of 0.1 mg/mL or higher, followed by gentle mixing and dilution in appropriate buffer for your assay.

Step-by-step protocol:

1. Centrifuge the vial:
   Before opening, briefly centrifuge the vial to ensure all lyophilized protein is at the bottom and not lost on the cap or tube walls.

2. Reconstitution:

   • Add sterile water or sterile PBS to the vial.
   • The recommended concentration for reconstitution is 0.1 mg/mL (e.g., add 1 mL to 0.1 mg of protein).
   • Gently mix by swirling or tapping; avoid vigorous shaking or vortexing to prevent protein denaturation and foaming.
   • Allow the protein to dissolve for 15–30 minutes at room temperature with gentle agitation.

3. Dilution for cell culture:

   • After reconstitution, dilute the protein to your working concentration using cell culture medium or buffer containing a carrier protein (e.g., 0.1% BSA, 10% FBS, or 5% HSA) to minimize adsorption and loss of activity, especially at low concentrations.
   • For serum-free or animal experiments, use trehalose as a stabilizer instead of animal-derived carrier proteins.

4. Aliquot and storage:

   • For short-term use (up to one week), store the reconstituted protein at 2–8°C.
   • For long-term storage, aliquot the diluted protein (with carrier protein or trehalose) and freeze at –20°C to –80°C. Addition of 5–50% glycerol can further stabilize the protein for extended storage.

5. Usage:

   • Thaw aliquots on ice and avoid repeated freeze-thaw cycles.
   • Add the protein directly to cell culture medium at the desired final concentration, optimizing based on your experimental requirements.

Additional notes:

• Always consult the product-specific Certificate of Analysis (CoA) for any unique instructions or buffer requirements.
• Avoid reconstituting to concentrations below 0.1 mg/mL unless specifically recommended, as lower concentrations may increase adsorption losses.
• Optimal working concentrations and dilutions should be empirically determined for each cell type and assay.

Summary Table:

This protocol ensures maximal recovery, stability, and bioactivity of BMPR-IA for cell culture applications.